RxDoctor Payments Data

Fredrick Ferris, MD

Internal Medicine · St Paul, MNNPI 1316953854

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,290 of the $6,252 with a category attached, or 84.6%. Sanofi US Services Inc. accounts for 84.6% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $5,339 and has fallen 99.7% since, to $17 in 2025. Among internal medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,252in general payments, 2019–2025

Across 66 payments — averaging $94.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$5K
  • Amgen$236
  • Novo Nordisk$133
  • Kowa Pharmaceuticals America, Inc.$88
  • Johnson & Johnson$83
  • Pfizer$47
  • plus $374 from 17 others

What the payments were for

  • Consulting fees$5,29085%
  • Food & beverage$95015%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,252 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$27,721
Medicare patients
88
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$49,932
XareltoRivaroxaban31$40,608
TrulicityDulaglutide28$32,456
EliquisApixaban25$21,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,161
Breo ElliptaFluticasone/Vilanterol17$14,151
MounjaroTirzepatide11$11,827
Lacosamide12$4,005
Memantine Hcl ErMemantine Hcl25$2,768
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,336
Atorvastatin Calcium136$1,715
Metoprolol Succinate80$1,606
CholestyramineCholestyramine (With Sugar)16$1,599
Bupropion XlBupropion Hcl46$1,593
SynthroidLevothyroxine Sodium13$1,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$15$49,93240 claims
Lilly USA, LLCTrulicity, Mounjaro$27$44,28339 claims
Johnson & JohnsonXarelto$83$40,60831 claims
GSKTrelegy Ellipta, Breo Ellipta$13$33,31145 claims
PfizerEliquis$47$21,42525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,924 internal medicine providers in Minnesota.

Other internal medicine in St Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →